ICPT · Intercept Pharmaceuticals
Acquired Company
Alfasigma completed the acquisition of Intercept Pharmaceuticals, Inc. on 11/8/2023, paying USD 19.00 per share in cash.
Acquired by Alfasigma S.p.A. Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$19.00
Open
$19.00
Volume
N/A
Day Range
$19.00 - $19.00
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
3.13%
Institutional Own.
81.30%
Qtr Updated
Jun 30th 2024